<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696822</url>
  </required_header>
  <id_info>
    <org_study_id>NP-002</org_study_id>
    <nct_id>NCT04696822</nct_id>
  </id_info>
  <brief_title>Bioavailability of Nasal Epinephrine</brief_title>
  <official_title>Bioavailability Comparison of Epinephrine Following a Single Nasal Dose of Microspheres Powder With Epinephrine Intramuscular Injection in Adults With Seasonal Allergic Rhinitis With and Without Nasal Allergen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nasus Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nasus Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of&#xD;
      FMXIN002 Microspheres Powder with Epinephrine 0.3 mg Intramuscular Injection in Adult&#xD;
      Subjects with Seasonal Allergic Rhinitis with and without Nasal Allergen Challenge&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Open-label, single-dose, two-period, three-treatment, fixed-sequence,&#xD;
      comparative bioavailability study Study Population: Non-smoking, male and female subjects,&#xD;
      from 18 to 55 years of age with known history of hay fever, seasonal allergies, or rhinitis&#xD;
      during the last year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, single-dose, two-period, three-treatment, fixed-sequence, comparative bioavailability study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epinephrine in blood - Cmax</measure>
    <time_frame>-1 hour to 8 hours post-dose</time_frame>
    <description>pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine in blood- Tmax</measure>
    <time_frame>-1 hour to 8 hours post-dose</time_frame>
    <description>pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine in blood- AUC</measure>
    <time_frame>-1 hour to 8 hours post-dose</time_frame>
    <description>pharmacokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine in blood- T half</measure>
    <time_frame>-1 hour to 8 hours post-dose</time_frame>
    <description>pharmacokinetic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body temperature</measure>
    <time_frame>morning</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level in blood</measure>
    <time_frame>at check-in morning</time_frame>
    <description>Safety Monitoring, blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood hematocrit</measure>
    <time_frame>check-in morning</time_frame>
    <description>Safety Monitoring: the ratio of the volume of red blood cells to the total volume of blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Prior to drug administration</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Prior to drug administration</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>15 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>15 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>30 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>30 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>45 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>45 minutes</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 hour</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>1 hour</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>2 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4 hours post-dose</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>4 hours post-dose</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>3 hours prior to drug administration</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>45 minutes</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Nasal Product, 1.6 mg</intervention_name>
    <description>Single dose Nasal powder spray without allergen challenge</description>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <other_name>FMXIN002 Microspheres Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine nasal product, 1.6 mg + allergen</intervention_name>
    <description>Single dose Nasal powder spray with allergen challenge</description>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <other_name>FMXIN002 Microspheres Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Injection 0.3 mg</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <other_name>EpiPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Nasal Product, 3.2 mg</intervention_name>
    <description>Twice dose Nasal powder spray without allergen challenge</description>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <other_name>FMXIN002 Microspheres Powder, double dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Nasal Product, 3.2 mg + allergen</intervention_name>
    <description>Twice dose Nasal powder spray with allergen challenge</description>
    <arm_group_label>Adults with seasonal allergic rhinitis</arm_group_label>
    <other_name>FMXIN002 Microspheres Powder, double dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The following inclusion criteria will be assessed at screening (within 28 days prior to the&#xD;
        first drug administration):&#xD;
&#xD;
          1. Non-smoking, male and female subjects from 18 to 55 years of age.&#xD;
&#xD;
          2. Documented Positive skin allergy test during the last year.&#xD;
&#xD;
          3. History of hay fever, seasonal allergies, or rhinitis.&#xD;
&#xD;
          4. BMI ≥18 and &lt;=30 kg/m2.&#xD;
&#xD;
          5. Females may be of childbearing or non-childbearing potential:&#xD;
&#xD;
               -  Childbearing potential:&#xD;
&#xD;
                  o Physically capable of becoming pregnant&#xD;
&#xD;
               -  Non-childbearing potential:&#xD;
&#xD;
                    -  Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral&#xD;
                       tubal ligation); and/or&#xD;
&#xD;
                    -  Postmenopausal (no menstrual period for at least 12 consecutive months&#xD;
                       without any other medical cause.&#xD;
&#xD;
          6. Willing to use acceptable, effective methods of contraception.&#xD;
&#xD;
          7. Able to tolerate venipuncture.&#xD;
&#xD;
          8. Be informed of the nature of the study and give written consent prior to any study&#xD;
             procedure.&#xD;
&#xD;
          9. Willing and being able to remain in the clinic for the entire duration of the&#xD;
             confinement period.&#xD;
&#xD;
         10. Have good intravenous access on both arms and hands.&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
             Known history or presence of clinically significant neurologic, hematologic,&#xD;
             endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or&#xD;
             cardiovascular disease or any other condition which, in the opinion of the&#xD;
             Investigator, would jeopardize the safety of the subject or impact the validity of the&#xD;
             study results.&#xD;
&#xD;
             Known or suspected carcinoma. Known history or presence of hypersensitivity or&#xD;
             idiosyncratic reaction to epinephrine, sulfite, other excipients of epinephrine&#xD;
             auto-injector, or any other drug substances with similar activity.&#xD;
&#xD;
             Known history or presence of clinically significant lactose, galactose, or fructose&#xD;
             intolerance.&#xD;
&#xD;
             Known history or presence of cardiac arrythmias, coronary artery disease or organic&#xD;
             heart disease.&#xD;
&#xD;
             Known history or presence of hyperthyroidism. Known history or presence of diabetes.&#xD;
             Known history or presence of Parkinson's disease. Known history or presence of any&#xD;
             food allergy. Presence of hepatic or renal dysfunction. Presence of nostril or septum&#xD;
             piercing. Presence of abnormal nasal anatomy (e.g., polyps, unilateral or bilateral&#xD;
             abnormalities of the nares, nasal turbinates, or septum including deviated septum).&#xD;
&#xD;
             History of nasal surgery. Presence of a medical condition requiring regular medication&#xD;
             (prescription and/or over-the-counter) with systemic absorption.&#xD;
&#xD;
             History of drug or alcohol addiction requiring treatment or positive alcohol breath&#xD;
             test at check-in.&#xD;
&#xD;
             Any acute illness (e.g. cold, acute infection) which is considered significant by the&#xD;
             Investigator and that has not resolved within 7 days before the first drug&#xD;
             administration.&#xD;
&#xD;
             Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.&#xD;
&#xD;
             Positive test result for urine drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and&#xD;
             tricyclic antidepressants) or urine cotinine.&#xD;
&#xD;
             Difficulty fasting or consuming standard meals. Inability to communicate well with the&#xD;
             Investigators and staff (e.g., language problem, poor mental development or impaired&#xD;
             cerebral function).&#xD;
&#xD;
             Non-cooperative or unwilling to sign consent form or unwilling to attend scheduled&#xD;
             clinic visits and/or comply with the study protocol.&#xD;
&#xD;
             Use of tobacco or nicotine-containing products within 6 months prior to drug&#xD;
             administration.&#xD;
&#xD;
             Females who:&#xD;
&#xD;
               -  Have discontinued or changed the use of implanted, intrauterine, intravaginal, or&#xD;
                  injected hormonal contraceptives within 6 months prior to drug administration;&#xD;
&#xD;
               -  Have discontinued or changed the use of oral or patch hormonal contraceptives&#xD;
                  within 1 month prior to drug administration;&#xD;
&#xD;
               -  Are pregnant (serum hCG consistent with pregnancy); or&#xD;
&#xD;
               -  Are lactating.&#xD;
&#xD;
             Donation or loss of whole blood (including clinical trials):&#xD;
&#xD;
               -  ≥50 mL and &lt;500 mL within 30 days prior to drug administration;&#xD;
&#xD;
               -  ≥500 mL within 56 days prior to drug administration. Participation in a clinical&#xD;
                  trial that involved administration of an investigational medicinal product within&#xD;
                  30 days prior to drug administration, or recent participation in a clinical&#xD;
                  investigation that, in the opinion of the Investigator, would jeopardize subject&#xD;
                  safety or the integrity of the study results.&#xD;
&#xD;
             On a special diet within 30 days prior to drug administration (e.g., liquid, protein,&#xD;
             raw food diet).&#xD;
&#xD;
             Have had a tattoo or body piercing within 30 days prior to drug administration. Have&#xD;
             clinically significant findings in vital signs measurements at screening. Systolic&#xD;
             blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic&#xD;
             blood pressure decrease in value by more than 10 mmHg, from supine or sitting to&#xD;
             standing position during orthostatic blood pressure measurement taken at screening.&#xD;
&#xD;
             Have clinically significant findings in a 12-lead ECG. Have clinically significant&#xD;
             abnormal laboratory values and hemoglobin &lt;135 g/L for males or &lt;120 g/L for females&#xD;
             at screening.&#xD;
&#xD;
             Have significant diseases at the screening. Have clinically significant findings from&#xD;
             a physical examination.&#xD;
&#xD;
             Use of the following drugs within 14 days prior to drug administration:&#xD;
&#xD;
               -  Alpha-adrenergic blocking drugs (e.g., phentolamine);&#xD;
&#xD;
               -  Anti-arrhythmics;&#xD;
&#xD;
               -  Beta-adrenergic blocking drugs (e.g., propranolol);&#xD;
&#xD;
               -  Cardiac glycosides;&#xD;
&#xD;
               -  Diuretics;&#xD;
&#xD;
               -  Drugs having an effect on cytochrome P450 (CYP450);&#xD;
&#xD;
               -  Enzyme-altering drugs (e.g., barbiturates, phenothiazines, cimetidine,&#xD;
                  carbamazepine, etc.);&#xD;
&#xD;
               -  Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism;&#xD;
&#xD;
               -  Ergot alkaloids;&#xD;
&#xD;
               -  Levothyroxine sodium;&#xD;
&#xD;
               -  Monoamine oxidase inhibitors;&#xD;
&#xD;
               -  Oral or topical corticosteroids;&#xD;
&#xD;
               -  Phenylephrine;&#xD;
&#xD;
               -  Reserpine-type or clonidine-type antihypertensives;&#xD;
&#xD;
               -  Sodium cromoglycate; or&#xD;
&#xD;
               -  Tricyclic antidepressants.&#xD;
&#xD;
             Use of the following drugs within 7 days prior to drug administration:&#xD;
&#xD;
               -  Nasal decongestants;&#xD;
&#xD;
               -  Nonsteroidal anti-inflammatory drugs (NSAIDs); or&#xD;
&#xD;
               -  Oral or topical antihistamines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoseph Caraco, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Center, Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

